PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Urovant licenses overactive bladder drug to Pierre Fabre

Urovant Sciences and Pierre Fabre Médicament have entered into an exclusive license agreement allowing the French pharma/cosmetics company to register and commercialize vibegron for the treatment of overactive bladder in the European Economic Area, UK and Switzerland.

The deal also includes some optional territories, such as the French-speaking countries of Sub-Saharan Africa, Turkey and certain Eastern European countries. California-based Urovant — a subsidiary of Sumitovant Biopharma — will retain full rights in the U.S. and other select markets.

Urovant will receive up to $75 million in an upfront payment, regulatory and sales milestones as well as sales royalties from Pierre Fabre.

The drug, branded as Gemtesa, won the U.S. FDA nod in Dec 2020. Gemtesa is a selective beta-3 adrenergic agonist that affects the muscles in the bladder.

The partners will share responsibility for vibegron clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant will also provide manufacturing services to Pierre Fabre.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026